InvestSMART

BTC Health Ltd (ASX: BTC) - Announcements

- Current share price for BTC : $0.060

ASX company news and announcements for BTC Health Ltd (BTC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All BTC Health Ltd (BTC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than BTC Health Ltd (BTC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for BTC Health Ltd (BTC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$21 Preliminary Final Report - Appendix 4E 28 Aug 2007 10:59AM $0.345 $0.060 fallen by 82.61%
$21 To invest $2 million in Hearing Technology Company Sensear 19 Jun 2007 8:31AM $0.365 $0.060 fallen by 83.56%
$21 Half Yearly Report 27 Feb 2007 6:40PM $0.380 $0.060 fallen by 84.21%
$21 Announcement re Stem Cell Sciences and Merck & Co 21 Feb 2007 8:27AM $0.420 $0.060 fallen by 85.71%
$21 Appendix 3D - Changes relating to buy-back 12 Jan 2007 11:58AM $0.420 $0.060 fallen by 85.71%
$21 Preliminary Final Report 13 Sep 2006 10:39AM $0.435 $0.060 fallen by 86.21%
$21 Half Yearly Report/Half Year Accounts 15 Mar 2006 6:17PM $0.420 $0.060 fallen by 85.71%
$21 Stem Cell Sciences Advances Towards 1st Cell Therapy Program 16 Nov 2005 9:50AM $0.395 $0.060 fallen by 84.81%
$21 Stem Cell Sciences Agreement with Lexicon Genetics 4 Nov 2005 9:14AM $0.405 $0.060 fallen by 85.19%
$21 On-Market Buy-Back 2 Nov 2005 9:59AM $0.410 $0.060 fallen by 85.37%
$21 Stem Cell Sciences announces agmt with Chemicon Intl 7 Oct 2005 9:40AM n/a $0.060 n/a
$21 Preliminary Final Report for Year Ended 30 June 2005 13 Sep 2005 5:01PM $0.400 $0.060 fallen by 85%
$21 Stem Cell Sciences secures licencing deal with Deltagen 6 Sep 2005 8:55AM $0.390 $0.060 fallen by 84.62%
$21 XRT Ltd secures new investors 29 Aug 2005 10:05AM $0.405 $0.060 fallen by 85.19%
$21 Stem Cell Sciences to commercialise Neural Stem Cell Tech. 17 Aug 2005 10:15AM $0.390 $0.060 fallen by 84.62%
$21 XRT Ltd signs technology licence agreement with Gatan Inc 1 Jun 2005 10:05AM $0.335 $0.060 fallen by 82.09%
$21 Phylogica EGM approves BTC acquisition of 28% shareholding 25 Jan 2005 3:04PM $0.415 $0.060 fallen by 85.54%
$21 Sale of investment in Xenome 25 Nov 2004 5:02PM $0.360 $0.060 fallen by 83.33%
$21 PRR's ann: Prima Biomed Raises $10 Million 27 Oct 2004 9:19AM $0.375 $0.060 fallen by 84%
$21 Commitment to Invest in Prima Biomed 27 Oct 2004 9:05AM $0.375 $0.060 fallen by 84%
$21 Xenome into Clinical Trials of Xen2174 Pain Relief Compound 20 Jul 2004 9:10AM $0.435 $0.060 fallen by 86.21%
$21 Takes 23% stake in Continence Control Systems 24 Jun 2004 9:27AM $0.420 $0.060 fallen by 85.71%
$21 New investment in leading nanotechnology co. Starpharma 18 Mar 2004 9:32AM $0.445 $0.060 fallen by 86.52%
$21 To Acquire Management Rights & Equity from Challenger 24 Dec 2003 3:04PM $0.470 $0.060 fallen by 87.23%
$21 Investee company Alchemia announces $21m underwritten IPO 10 Nov 2003 9:44AM $0.470 $0.060 fallen by 87.23%

526 - 550 of 557 results

Page 22 of 23

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.